Document is current
Any future updates will be listed below
-
Authors
Kwon, Hyun-Jin
Shin, Ji Eun
Khan, Amir
Park, So Yeon
Kim, Jiyoung
Lee, Jee-Young
Lee, Doohyun
Lee, Seungyeon
Im, Chun Young
Moon, Heegyum
Han, Ye Ri
Tamai, Minori
Akahane, Koshi
Inukai, Takeshi
Lee, Wonhwa
Kim, Hyelim
Kim, Hong Nam
Ahn, Sung-Min
Park, Hyun Woo
Kim, Dong-Wook
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2020M3F7A1094077, 2017M3A9G4052951)
- License Information
-
More Information
Article History
Received: 26 October 2024
Accepted: 5 March 2025
First Online: 14 April 2025
Declarations
:
: All human samples were obtained from the Korea Leukemia Bank and the protocol was approved by the Institutional Review Board. Patient consent was obtained in accordance with the Declaration of Helsinki. Animal experiments were approved by Institutional Animal Care and Use Committee (IACUC), the preclinical research center, Daegu-Gyeongbuk Medical Innovation Foundation (Documentation KMEDI-22011801–01).
: Not applicable.
: HJK, JYK, and SMA are employees of ImmunoForge, Inc., and KF1601 is a proprietary drug candidate of ImmunoForge, Inc. The remaining authors declare no conflict of interests.
